Table 1.
Summary of preclinically developed ZIKV E-targeting neutralizing mAbs with therapeutic potential
| Name | Source | Target region | In vitro efficacy | In vivo efficacy | Structure | Ref |
|---|---|---|---|---|---|---|
| Z3L1 | Human | EDI tertiary epitopes | Neutralizes ZIKV Asian strain (IC50: 170–240 ng/ml) | Post-exposure treatment protects Ifnar1-deficient mice from ZIKV (American strain) | Yes | 6 |
| ZIKV-117 | Human | EDII quaternary epitopes | Neutralizes ZIKV African, Asian, and American strains (IC50: 5–25 ng/ml) | Prophylactically and therapeutically protects ZIKV (African and American strain)-infected, anti-Ifnar1-treated wild-type mice from mortality, fetal infection and fetal demise | Yes | 7, 10 |
| ZKA190 | Human | Part of the EDI-III linker and EDIII-LR region | Neutralizes ZIKV African, Asian, and American strains (IC50: 0.6–8 ng/ml) | Prophylactically and therapeutically protects A129 and/or AG129 mice from ZIKV (African and American strains)-caused morbidity and mortality | Yes | 4 |
| SMZAb2 SMZAb1 SMZAb5 | Human |
EDII EDIII EDIII |
Neutralize ZIKV American strain (IC50: 189, 5.4, and 3.8 ng/ml for SMZAb2, 1, and 5, respectively) | Cocktail of LALA mutants of these three mAbs prophylactically protects NHPs from ZIKV (American strain) replication | ND | 3 |
| Z23 | Human | EDIII tertiary epitopes | Neutralizes ZIKV Asian strain (IC50: 370–560 ng/ml) | Post-exposure treatment protects A129 mice from ZIKV (American strain) | Yes | 6 |
|
ZV-54 ZV-67 |
Mouse | EDIII-LR region | Neutralize ZIKV African, Asian, and American strains | Prophylactically protect ZIKV (African strain)-infected, anti-Ifnar-treated wild-type mice from viremia, weight loss, and mortality |
ND Yes |
5 |
| ZKA64 | Human | EDIII | Neutralizes ZIKV African strain (IC50: 93 ng/ml) | ZKA64-LALA mutant prophylactically and therapeutically protects A129 mice against ZIKV (African strain)-caused weight loss and lethality | ND | 8 |
|
m301 m302 |
Human | EDIII cryptic C–Cʹ loop epitope | Neutralize ZIKV Asian and American strains (IC50: ~2 μM) | m301/m302 combination shows moderate prophylactic and therapeutic protection of AG6 mice against ZIKV (Asian strain)-caused lethality | ND | 9 |
IC50 median inhibitory concentration, anti-Ifnar antibodies against type I interferon receptor, LALA mutant incorporation of L234A and L235A mutations into the IgG-Fc, LR lateral ridge, and ND not determined